Trial Profile

Opicapone Treatment Initiation Open-Label Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Opicapone (Primary) ; Levodopa/carbidopa
Indications Parkinson's disease
Focus Adverse reactions; Therapeutic Use
Acronyms OPTI-ON
Sponsors Neurocrine Biosciences

Most Recent Events

27 Apr 2023 Results(n=164) assessing patient-reported outcomes (PROs) from the Opicapone Treatment presented at the 75th Annual Meeting of the American Academy of Neurology 2023
23 Nov 2022 Status changed from active, no longer recruiting to completed.
24 Oct 2022 According to Neurocrine Biosciences media release, the company presented data detailing the baseline characteristics of patients with Parkinson's disease at the 2022 American Neurological Association Annual Meeting (ANA2022) being held from 22nd-25th October.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com